EP
CVAC

Eversept Partners’s CureVac CVAC Stock Holding History

Eversept Partners’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-515,691
Closed -$1.56M – 77
2024
Q1 		$1.56M Buy
515,691
+18,779
+4% +$65.9K 0.1% 65
2023
Q4 		$2.09M Sell
496,912
-19,882
-4% -$108K 0.18% 51
2023
Q3 		$3.53M Buy
516,794
+159,452
+45% +$1.41M 0.3% 53
2023
Q2 		$3.72M Buy
+357,342
New +$3.2M 0.31% 47
2022
Q1 		– Sell
-85,017
Closed -$2.92M – 92
2021
Q4 		$2.92M Buy
+85,017
New +$3.42M 0.19% 74

Other funds holding CVAC

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's CVAC Position: Q2 2024 in Review

Eversept Partners sold out of CureVac (CVAC) in Q2 2024, closing a stake of 515,691 shares — an estimated $1.56M sold.

Eversept Partners first reported a position in CVAC in Q4 2021 and held it in 5 quarters. The position peaked at $3.72M in Q2 2023. 87 funds tracked by Wall St. Rank hold CVAC as of Q2 2024.

  • Eversept Partners reported no remaining CureVac position as of Q2 2024 after selling out during the quarter.
  • Eversept Partners sold 515,691 CureVac shares in Q2 2024, an estimated $1.56M.
  • Eversept Partners first reported a position in CureVac in Q4 2021 and held it in 5 quarters.
  • Eversept Partners's CureVac position peaked at $3.72M in Q2 2023.
  • 87 funds tracked by Wall St. Rank held CureVac as of Q2 2024.

Based on Eversept Partners's 13F filing for Q2 2024, filed 14 Aug 2024.